MHRA Orphan Register Expands Again as Rare-Disease Therapies Move In and Out of Review
The MHRA’s Orphan Register continues to shift as rare-disease medicines are added, removed, renamed, or moved into the expired list. The latest updates show a regulatory system that is not static but actively tracking product status, market exclusivity, and authorized orphan indications across a fast-moving therapeutic class. For clinicians treating rare disease, the register is more than an administrative ledger. It is the live reference point for whether a medicine remains formally recognized in the UK orphan framework, which can affect access, eligibility, and the practical interpretation of a product’s regulatory position.
The most recent October 2026 entry added CRESEMBA 40 mg hard capsules under OD1 and OD2, removed Oxbryta 500 mg film-coated tablets from the orphan register and placed it on the expired orphan register, and added Lunsumio 5 mg and 45 mg solution for injection under OD1. Those movements are typical of the register’s cadence: one product enters as another exits, while others remain in place with amended exclusivity dates, indication updates, or packaging changes. In rare disease, these details matter because the regulatory life span of a medicine often evolves alongside the evidence base, commercial status, and the need to preserve or revise an orphan designation.
A close reading of the 2025 and 2026 entries reveals a register that has absorbed a steady stream of new therapies spanning hematology, metabolic disease, ophthalmology, pulmonary disease, neurology, and immunology. The 2026 additions include Romvimza, IMCIVREE, ZYNYZ, Koselugo, Wayrilz, Vyjuvek, and renewed entries such as Kanuma and Strensiq. Earlier 2025 entries brought in Winrevair, Givinostat, FABHALTA, Qalsody, Akantior, Adzynma, and Aucatzyl. This is the regulatory footprint of a field in which increasingly targeted biologics, enzyme therapies, gene-based interventions, and precision oncology products are finding formal orphan status.
Regulatory movement is not just about addition. Several entries were removed or transferred to the expired register over the same period, including ADAKVEO, Raxone, Bylvay after expiry updates, Hetlioz, ADCETRIS, Cometriq, Gazyvaro, Revestive, Translarna, Hepcludex, and SCENESSE. The pattern reflects a structured lifecycle: orphan status is not permanent by default, and exclusivity periods eventually expire, indications can be revised, or products can move into the expired register when the status changes. In practice, that means prescribers and pharmacists need to check the current register rather than rely on older assumptions about orphan designation.
Market exclusivity amendments are a recurring theme. Some entries saw their expiration dates extended, such as Fintepla, Trecondi, and Spexotras. Others were updated for orphan indication changes, including Soliris, TAKHZYRO, Kinpeygo, Onivyde pegylated liposomal, and Blinatumomab. These revisions matter because orphan designation sits at the intersection of commercial incentive and clinical access. A longer exclusivity window can support ongoing development in small patient populations where randomized evidence is difficult to generate, but it also reinforces the need for clear post-authorization surveillance and sustained reassessment of therapeutic value.
The 2024 and 2025 register history shows how rapidly rare-disease portfolios are changing. Casgevy entered the register for β thalassaemia and sickle cell disease; Yescarta, Kymriah, Carvykti, Tecartus, Abecma, and Breyanzi reflect the growing role of advanced cellular therapies in hematologic malignancy. At the same time, products such as Wakix were withdrawn and others were reclassified or expired. The regulatory picture now extends well beyond traditional small-molecule orphan drugs and into gene therapy, autologous cell therapy, monoclonal antibodies, and recombinant biologics aimed at highly specific disease mechanisms.
From a bedside standpoint, the register’s value lies in precision. For rare disorders, where patient numbers are low and treatment pathways are often specialized, the difference between an active orphan listing and an expired one can change how a product is identified in regulatory checks, formulary review, and procurement. It also helps explain why so many entries carry variant strengths, new pharmaceutical forms, or packaging-specific updates. A product can remain clinically recognizable while its regulatory representation changes in ways that matter to systems managing access and continuity of care.
The distinctions are practical, not theoretical.
One striking feature of the 2026 update trail is the repeated addition of specific dosage forms and strengths, such as PREVYMIS granules in sachet, Voranigo tablets with extended exclusivity, Ogsiveo tablets, Kaftrio granules, and Vyvgart solution. These are not cosmetic edits. They reflect the way orphan medicines are often developed for discrete age groups, swallowing limitations, infusion requirements, or formulation-specific tolerability needs. In rare disease, the wrong formulation can be a real barrier to treatment, so a register that tracks exact presentations is clinically relevant.
The broader message from the MHRA list is straightforward: orphan medicine regulation is active, iterative, and tightly linked to the evolving therapeutic pipeline. The register now captures a mature rare-disease market in which older products age out, newer products arrive quickly, and many agents undergo repeated indication or exclusivity revisions. For clinicians, the practical task is to verify current status against the live register before making assumptions about orphan designation, especially when prescribing across specialty centers or when a patient’s therapy sits near the boundary between active registration and expired status.